Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
Phase 2/Phase 3
Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including
pulmonary vascular disease and pulmonary fibrosis.
Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic
pulmonary fibrosis (IPF), a condition for which no established treatment is available.
The present trial investigates a possible use of bosentan, which is currently approved for
the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to
a new category of patients suffering from IPF.
It was decided to offer Open Label treatment (bosentan) for patients willing to continue in
the BUILD 1 study.
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan
sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary
arterial hypertension (PAH).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.